Cardiolipin Antibodies Panel (IgG, IgA & IgM) Test in UAE | 750 AED | DHA Licensed Facility

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139). Enzyme Immunoassay (ELISA/EIA) methodology delivers clinically validated quantitative IgG, IgA, and IgM cardiolipin antibody titres essential for antiphospholipid syndrome (APS) risk stratification.

Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection. VIP Mobile Phlebotomy available 8 AM – 11 PM, 7 days a week. Dual 2-SST sample protocol (4 mL serum minimum 3 mL), refrigerated or frozen transport ensuring analyte stability.

Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed clinical advisors. Direct physician-to-physician consultation pathway available for complex serological profiles.

Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731. We coordinate with all major UAE insurers for seamless pre-authorization.

Test Overview & Methodology

The Cardiolipin Antibodies Panel (IgG, IgA & IgM) is a serological investigation that quantifies anti-cardiolipin antibodies — key biomarkers in the diagnostic workup of antiphospholipid syndrome (APS) and thromboembolic risk assessment. This triple-isotype panel is essential for evaluating unexplained recurrent pregnancy loss, arterial or venous thrombosis, and thrombocytopenia in both obstetric and cardiovascular clinical contexts.

Parameter	Our Cardiolipin Panel (ELISA)	Closest Alternative (CLIA / Multiplex Bead)
Analytical Precision (CV%)	≤ 5% Intra-Assay \| ≤ 8% Inter-Assay	5% – 12% variability; lot-to-lot inconsistency reported
Methodology	Enzyme Immunoassay (ELISA/EIA) — Gold Standard per ISTH Guidelines	Chemiluminescence Immunoassay (CLIA) — Semi-quantitative; limited isotype resolution
Isotype Detection	Full Triple Isotype: IgG + IgA + IgM (Independent Titres)	Often IgG/IgM only; IgA omitted or unreliably reported
Turnaround Time	Same-Day Reporting (Sample received by 9 AM, Mon–Sat)	24–72 hours typical; outsourced to referral labs
Regulatory Compliance	ISO 9001:2015 \| DHA Facility License 1143 \| UAE PDPL Compliant	Variable; may lack UAE-specific accreditation

Physician Insight & Safety Protocols

Clinical Note from Dr. Ajay Singh (DHA License: 36234132):

"A positive cardiolipin antibody result — whether IgG, IgA, or IgM — must always be interpreted within the complete clinical picture. A single positive titre does not automatically confer a diagnosis of antiphospholipid syndrome; current international consensus requires persistence of moderate-to-high titres on two occasions at least 12 weeks apart, in conjunction with clinical thrombotic or obstetric criteria. I strongly advise all patients to discuss their results with their treating physician before drawing any independent conclusions."

Medication Safety Advisory

⚠ MEDICATION SAFETY WARNING

Do not discontinue prescribed anticoagulant, antiplatelet, or immunomodulatory medication without consulting your doctor. Abrupt cessation of blood thinners (e.g., warfarin, rivaroxaban, apixaban, clopidogrel, or low-dose aspirin) in patients with known or suspected APS can precipitate life-threatening thrombotic events including pulmonary embolism, stroke, or deep vein thrombosis.

Exclusion Criteria & Emergency Red Flags

Exclusion Criteria for Home Collection: Active febrile illness (>38.5°C) within 24 hours of collection; known acute thromboembolic event within the past 7 days requiring inpatient management; haemodynamic instability (systolic BP <90 mmHg or heart rate >120 bpm at rest).
Emergency Red Flags — Seek Immediate Medical Attention (Call 998 or visit nearest ER): Sudden-onset pleuritic chest pain with dyspnoea (suspect pulmonary embolism); unilateral leg swelling with erythema and warmth (suspect deep vein thrombosis); acute confusional state with focal neurological deficit (suspect stroke or cerebral venous sinus thrombosis); visual disturbances with severe headache in a known APS patient.
Sample Rejection Criteria: Haemolysed, lipaemic, or icteric serum samples; insufficient volume (<3 mL per SST); samples collected in incorrect tube type; samples exceeding 48 hours in transit without refrigeration.

Patient FAQ & Clinical Guidance

1. What is the Cardiolipin Antibodies IgG, IgA & IgM Panel, and why would my doctor order it?

Answer: The Cardiolipin Antibodies Panel is a quantitative serological test that measures three distinct immunoglobulin isotypes — IgG, IgA, and IgM — directed against cardiolipin, a phospholipid found in mitochondrial and platelet membranes. Your physician may order this panel when there is clinical suspicion of antiphospholipid syndrome (APS), particularly in the context of unexplained recurrent miscarriages (≥3 consecutive losses before 10 weeks gestation), one or more unexplained venous or arterial thrombotic events, persistent thrombocytopenia, or prolonged activated partial thromboplastin time (aPTT) without a bleeding tendency, as the presence and persistence of these antibodies directly informs both diagnostic classification and long-term anticoagulation strategy.

2. Are there any risks, side effects, or special preparations required for this blood test?

Answer: No special preparation — including fasting — is required for the Cardiolipin Antibodies Panel; patients may eat, drink, and take their regular prescribed medications as normal prior to venipuncture. The blood draw itself carries minimal risk: temporary discomfort at the puncture site, a small bruise (haematoma), or, in fewer than 1 in 10,000 cases, a transient vasovagal response such as lightheadedness. Our DHA-licensed mobile phlebotomists follow strict aseptic technique using single-use, sterile closed-system devices, and the dual 2-SST collection protocol (4 mL total serum across two serum separator tubes, transported under refrigerated or frozen cold-chain conditions) ensures both sample integrity and patient safety throughout the process.

3. How quickly will I receive my Cardiolipin Antibodies Panel results, and what do positive results mean clinically?

Answer: Results are reported the same day when your sample is collected Monday through Saturday before 9 AM, with the quantitative IgG, IgA, and IgM cardiolipin antibody titres expressed in standardised GPL and MPL units (for IgG and IgM) alongside laboratory-specific reference ranges. A positive result — defined as moderate (>40 GPL/MPL) or high (>80 GPL/MPL) titre for IgG and/or IgM, or elevated IgA cardiolipin antibodies — indicates the presence of antiphospholipid antibodies but does not alone confirm antiphospholipid syndrome; clinical correlation with thrombotic history, obstetric history, and confirmatory testing (including lupus anticoagulant and anti-beta-2-glycoprotein I antibodies) repeated after a minimum 12-week interval is mandatory per the revised Sapporo-Sydney Classification Criteria to establish a definitive diagnosis and guide long-term management decisions.

UAE Regulatory & Data Privacy Adherence

DNA Labs UAE operates under the regulatory oversight of the Dubai Health Authority (DHA Facility License No. 1143) and adheres to the following UAE federal legal frameworks:

Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): All patient personal data, including test results and clinical history, are processed, stored, and transmitted in full compliance with PDPL requirements for consent, data minimization, and lawful processing.
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: Our digital health systems, electronic medical records, and telehealth consultation platforms comply with this law governing the use of ICT in healthcare delivery.
Federal Decree-Law No. 4 of 2016 on Medical Liability: All clinical procedures, including venipuncture and result interpretation, are conducted in accordance with the standards of care defined under this law, ensuring patient safety and professional accountability.
ISO 9001:2015 Quality Management System: Certified under Cert. No. INT/EGQ/2509DA/3139, our laboratory operations meet international standards for quality management, continuous improvement, and customer satisfaction.

Clinical & Logistical Metadata

Test Name	Cardiolipin Antibodies Panel (IgG, IgA & IgM)
Price (AED)	750
Turnaround Time	Same-day reporting (samples received Mon–Sat before 9 AM)
Sample Type / Matrix	Serum (2 SST, 4 mL total)
Methodology Used	Enzyme Immunoassay (ELISA/EIA)
ICD-10-CM Code	D68.61, R79.89
LOINC Code	48222-6
DHA Facility License & Laboratory Address	License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE